Compare DuPont de Nemours Inc (DD) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs Johnson & Johnson — how do they compare? DuPont de Nemours Inc trades at $130.57 (market cap $17.89B), while Johnson & Johnson trades at $261.35 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 34.5× DuPont de Nemours Inc's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold DuPont de Nemours Inc for 89 Days and Johnson & Johnson for 129 Days on average.
| DD | JNJ | |
|---|---|---|
Market Cap | $17.89B | $618.09B |
Volume | 816,409 | 6,050,983 |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $278.43 |
52-Week Low | $92.49 | $186.00 |
Typical Hold Time | 89 Days | 129 Days |
Enterprise Value | $19.28B | $646.37B |
Dividend Yield | 1.81% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $130.53, down 0.42% on the day, with a neutral technical signal and bearish moving average trend. The company reported a net loss of $779 million in 2025 despite beating EPS estimates in recent quarters, with revenue declining to $6.85 billion. Analyst consensus is bullish with 59% buy ratings, though the consensus price target of $95 is below the current price. Recent news highlights innovation in Tyvek materials and digital tools, alongside legal settlements over PFAS contamination.
The outlook is mixed: strong analyst support and product innovation offer upside, but recent profitability challenges, high P/E ratio, and legal liabilities pose risks. Earnings growth and margin recovery are critical for sustaining investor confidence amid volatile cash flows and competitive pressures.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
